Our math model found tradeoffs in MPOX vaccination strategies and supports smaller doses to protect a larger population at risk When there is a shortage of vaccine available in a public health crisis, one policy option is to offer the full dose to a small population or alternatively offer a smaller dose to a larger…
Real World Accuracy of Rapid Antigen vs PCR Tests for Infectious Omicron
Real world data from occupational safety programs revealed most Omicron cases were infectious for several days before being detectable by rapid antigen tests.
Better Health Policy for Successful Live Theater in COVID-19
The best health and economic policies for safe, successful, live theater in 2021-2023 will be dynamic – adapting protocols quickly to new scientific evidence, flexing capacity limits according to vaccination and testing. On Thursday April 1, 2021, the COVID Theatre Think Tank hosted a national town hall for the theatre industry to address the current…
Major League Sports Lessons in COVID-19
It’s been an honor to serve and learn as a member of the COVID-19 Sports and Society Working Group, co-chaired by ex-Obama healthcare head Andy Slavitt and the VP of Basketball Performance for NBA Minnesota Timberwolves Dr. Robby Sikka. The guys and I wrote down some key takeaways from the different COVID-19 prevention and testing…
Fall 2020 Scientific Speaking
Effective scientific communication is really hard This summer I met a few cast members from Saturday Night Live, including the comedian Mikey Day. I’m a big fan of the show and have watched it since old enough to stay up until 11:35pm on Saturdays. We talked about the their creative solutions for comedy during lock…
LatinX Inequity in Access to COVID Treatment Trials
For LatinX and Hispanic people burdened by COVID disease, where can they go for hope? An early pre-print of our report is now available here. What do we already know? Access to and patient enrollment in clinical trials of COVID-19 therapies is likely strongly impacted by where trials are launched. Our objectives were to evaluate…
Lessons from Cost-Effectiveness of HIV vaccines for COVID Vaccines
Will HIV vaccines compete with existing HIV prevention strategies? Who is doing COVID vaccine cost-effectiveness analysis? Fred Hutch Science Spotlight translated the math in our peer-reviewed paper published in the Journal of the International AIDS Society to explain the economic tradeoffs of delivering an HIV vaccine in Seattle in the future. Our prior review of…
Economic Roots of COVID-19 Racial Inequities
COVID-19 disparities persist in our most vulnerable communities, including low-income families and racial and ethnic minorities, partly because of the financial necessity to continue working, as well as the lack of employment opportunities that enable their residents to work remotely. They are more likely to be essential workers, and that increases their exposure to the…
Advanced Methods for Math Modeling the Epidemiology and Economics of Coronavirus
Pulled from the Infectious Economics archives, these articles provide recommendations for the design and development of robust mathematical models of COVID-19 epidemiology and economics to reduce uncertainty in decision-making and inform evidence-based public policy. Associations are easy; valid causal inference is hard If we want to be honest in evaluating the winners and losers in…
The Atlantic: People v. Cancer
People of lower socioeconomic status face higher cancer death rates than their counterparts. African American men suffer the highest cancer incidence rate of any racial or ethnic group. But these gaps in cancer care can be addressed through policy. What does the case of Medicaid expansion reveal about cancer disparities in America? And what will…